SI
SI
discoversearch

Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3053 142 0 INCY
Emcee:  ANGELIQUE LEE Type:  Unmoderated
INCY is involved in the mapping of the human genome and is supported by many major pharmeceutical companies. I bought in at 28 as a long-term buy when they started trading on the NASDAQ last week. They ahve been moving quite a bit since then, breaking new highs at closing all week. Friday their day low was 30, day high of 36. Anybody have recent info that might explain the fluctuation? Thanks, Angelique
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3053We could use a new moderator to update the board header and we also need a logo SI Ron (Hall Monitor)-November 6
3052More of the same from SITC2014.... immunotherapyofcancer.orgscaram(o)uche-November 6
3051>> 986 is gone from the pipeline chart << j l ?@lomu_j21m21 minutesscaram(o)uche-October 30
3050updated..... GILD - Idelalisib, GS-9901 (GS-9901 not confirmed PI3Kdelta, but lscaram(o)uche-October 29
3049Fun (and probably useless) factoid..... Dr. Khleif is also P.I. at the only siscaram(o)uche-October 24
3048Interesting. Don't think I ever put this abstract up, as it didn't honescaram(o)uche-October 23
3047Wo! finance.yahoo.com NewLink Genetics Announces Exclusive Worldwide Licensingscaram(o)uche-October 20
3046Updated...... Tuck has found another clinical-stage project from Rhizen. GILD scaram(o)uche-October 19
3045Was NOT expecting this..... clinicaltrials.govscaram(o)uche-October 17
3044Talked about panabinostat, and results showing recovery of marrow. Now therescaram(o)uche-October 17
3043986 is gone from the pipeline chart? Stepping in is 793 (no detail beyond "scaram(o)uche-October 16
3042>> Relative Bioavailability of the Baricitinib (LY3009104) Commercial Tablscaram(o)uche-October 14
3041PLoS One. 2014 Oct 7;9(10):e109799. doi: 10.1371/journal.pone.0109799. eCollectiscaram(o)uche-October 8
3040Housekeeping note...... Xeljanz did $68m in 2nd quarter. Psoriasis trial coscaram(o)uche-October 8
3039Yes. It promptly went to $70.scaram(o)uche-October 7
3038cool..... news.bms.com Bristol-Myers Squibb Announces Collaboration to Evaluascaram(o)uche-October 6
3037Looked like a dedicated seller ("capping") yesterday, on relatively hiscaram(o)uche-October 3
3036<i>Incyte will record this amount as contract revenue in the third quarterscaram(o)uche-October 2
3035Interesting trial...... clinicaltrials.gov nilotinib plus rux, Novartis trial,scaram(o)uche-October 2
3034It's only been two years? Sheesh, seems like forever. RA-BEAM fully enrollscaram(o)uche-September 29
3033GILD - Idelalisib INCY - INCB40093 TGTX - TGR-1202 INFI - IPI-145 and IPI-443 scaram(o)uche-September 17
3032BRUSSELS, Aug 8 (Reuters) - Belgian biotech group Galapagos said its partner Glanigel bates-August 8
3031I did substantially increase my GILD position, but lost out on INCY and TGTX, a Biotech Jim-June 18
3030This list back in play? Wouldn't it be surprising if GILD ended up in the cscaram(o)uche-June 16
3029 NEW YORK & WILMINGTON, Del.--(BUSINESS WIRE)-- Bristol-Myers Squibb Companynigel bates-May 27
3028"c-reactive proteins levels greater than 13 mg/dl" thestreet.comscaram(o)uche-May 14
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2014 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.